MC1193: Collaborative Care to Preserve Performance in Cancer (COPE)
PRIMARY OBJECTIVES:
I. Establish the comparative effectiveness of the Collaborative Care to Preserve Performance
in Cancer (COPE) trial arms in preserving functional status.
II. To assess the comparative cost-effectiveness and cost-utility of the COPE interventions.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients undergo enhanced usual care comprising telephonic monitoring, monthly status
reports, and an oncology care team for 6 months.
ARM II: Patients undergo enhanced usual care as in Arm I and participate in an
individualized conditioning program delivered by a local physical therapist and coordinated
by the Rehabilitation Care Manager (RCM) for 6 months.
ARM III: Patients undergo enhanced usual care as in Arm I, participate in an individualized
conditioning program coordinated by the RCM as in Arm II, and receive optimized pain
management through a Pain Care Manager (PCM) for 6 months.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Change in Acute Care CAT (APC) score in cancer patients out to 6 months.
An overall test using a linear contrast across the three arms will be used. If this is significant then tests between individual pairs of arms will follow. A mixed-effects regression model will allow use of multiple APC measurements per subject while allowing for an appropriate within-subject covariance structure. Time will be incorporated as a continuous variable, a polynomial function, or using assessment-specific indicator variables to determine the most parsimonious model that adequately describes the observed patterns.
Baseline to 6 months
No
Andrea Cheville, M.D.
Principal Investigator
Mayo Clinic
United States: Food and Drug Administration
MC1193
NCT01721343
November 2012
Name | Location |
---|---|
Mayo Clinic | Rochester, Minnesota 55905 |